Neuropathy Affecting Patents (Class 514/18.2)
  • Patent number: 9963492
    Abstract: Disclosed are protein brushes that mimic mucin in physical and functional characteristics. The protein brushes have a variable number of tandem repeats similar to natural mucin and are modified at a number of their tyrosine residues to introduce brush substituents that mimic the hydrogel nature of mucin.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: May 8, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Brian M. Seifried, Bradley D. Olsen
  • Patent number: 9068015
    Abstract: The present invention relates to the field of therapeutic use of proteins, genes and cells, in particular to the therapy based on the biological function of a secreted therapeutic protein, METRNL, in particular for the treatment of disorders of the nervous system. METRNL is a Nerve Survival and Growth factor with neuroprotective and/or neurogenesis effects.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: June 30, 2015
    Assignee: NsGene A/S
    Inventors: Jesper Roland Jorgensen, Lone Fjord-Larsen, Lars Ulrik Wahlberg, Nuno Miguel Gomes Andrade, Teit E. Johansen
  • Patent number: 9034826
    Abstract: The present invention is relevant to human medicine, and, in particular, to the use of Epidermal Growth Factor (EGF) in a pharmaceutical composition, said composition is administered through infiltration at the periphery of nerve trunks and/or ganglia, for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as ischemic neuritis. It is also relevant to an EGF containing composition, where this molecule can be formulated together with anesthetic or analgesic drugs, or encapsulated in microspheres, and their use for the morphofunctional restoration of peripheral nerves in painful, sensory-motor neuropathy, as well as in ischemic neuritis.
    Type: Grant
    Filed: December 26, 2013
    Date of Patent: May 19, 2015
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jose Ignacio Fernandez Montequin, Luis Saturnino Herrera Martinez, Jorge Amador Berlanga Acosta, Diana Garcia Del Barco Herrera, Danay Cibrian Vera, Gerardo Enrique Guillen Nieto, Raimundo Ubieta Gomez, Sonia Gonzalez Blanco, Vivian Maria Saez Martinez
  • Patent number: 9018173
    Abstract: N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2 blockers in pain therapeutics is limited by side effects. Reported herein is a means to suppress both inflammatory and neuropathic pain without directly blocking CaV2.2, but rather by inhibiting the binding of the axonal collapsin response mediator protein 2 (CRMP-2), a protein known to enhance CaV2.2 function. A 15 amino acid peptide of CRMP-2 fused to the protein transduction domain of the HIV tat protein (TAT CBD3) reduced meningeal blood flow induced by activation of the trigeminovascular system, prevented inflammation-induced tactile hypernociception induced by intraplantar formalin and nocifensive behavior following corneal capsaicin application, and reversed neuropathic hypernociception produced by the antiretroviral drug 2?,3?-dideoxycytidine. Preventing CRMP-2—mediated enhancement of CaV2.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: April 28, 2015
    Assignee: Indiana University Research and Technology Corp.
    Inventor: Rajesh Khanna
  • Patent number: 9006205
    Abstract: Alzheimer's disease (AD) is the most common human neurodegenerative disease of the CNS resulting in progressive neuronal death and memory loss. Despite intense investigations, no effective therapy is available to stop its onset or halt its progression. It was discovered that antisense oligonucleotide against neutral sphingomyelinase and GW4869, a chemical inhibitor of neutral sphingomyelinase, inhibit activation of glial cells and protect neurons in AD cell culture and animal models. These results suggest the following new treatment options for AD patients: Antisense oligonucleotide against neutral sphingomyelinase and GW4869.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: April 14, 2015
    Assignee: Rush University Medical Center
    Inventor: Kalipada Pahan
  • Patent number: 8992951
    Abstract: Novel formulations and methods for their use in treating neuropathology incident to trauma are provided. Multiple-component formulations of the invention, and especially those having four components, comprise biologically active compounds configured for preventing or reducing the incidence and severity of damage caused by neurotrauma. Formulations and methods of the invention effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma. Formulations and methods of the invention are especially useful in treating neurological trauma, such as those caused by sports injuries and improvised explosive devices in combat.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: March 31, 2015
    Assignee: Sapna Life Sciences Corporation
    Inventor: James Lorne Henry
  • Publication number: 20150087595
    Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
    Type: Application
    Filed: March 29, 2013
    Publication date: March 26, 2015
    Inventor: D. Travis Wilson
  • Patent number: 8986714
    Abstract: Novel formulations and methods for their use in treating neuropathology incident to trauma are provided. Multiple-component formulations of the invention, and especially those having four components, comprise biologically active compounds configured for preventing or reducing the incidence and severity of damage caused by neurotrauma. Formulations and methods of the invention effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma. Formulations and methods of the invention are especially useful in treating neurological trauma, such as those caused by sports injuries and improvised explosive devices in combat.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: March 24, 2015
    Assignee: Sapna Life Sciences Corporation
    Inventor: James Lorne Henry
  • Publication number: 20150072935
    Abstract: Provided are a composition and an external application for promoting muscle differentiation or improving muscle mass containing an amino acid derivative promoting muscle cell differentiation, a composition and an external application for alleviating muscle function deterioration caused by muscle damage and recovering damaged muscle containing the same, or a pharmaceutical composition and an external application for treating or improving a muscle deterioration disease containing the same.
    Type: Application
    Filed: November 5, 2014
    Publication date: March 12, 2015
    Applicant: NEOPHARM CO., LTD.
    Inventors: Bong-Woo KIM, Jeong Eun JEON, Se Kyoo JEONG, Yoon KIM
  • Patent number: 8974782
    Abstract: The present invention relates to a dosing regimen for use in the treatment of stroke. More particularly, the invention relates to the administration of two doses of anti-MAG antibodies for the treatment of ischemic and/or haemorrhagic stroke.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: March 10, 2015
    Assignee: Glaxo Group Limited
    Inventors: Bams Abila, Lori Ann Enney, Seth Paul Finklestein, Volker Germaschewski, Robert Ian Grundy, Elaine Alison Irving, Monica Simeoni
  • Patent number: 8957030
    Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 17, 2015
    Assignees: Cornell Research Foundation, Inc., Institute de Recherches Cliniques de Montreal
    Inventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
  • Publication number: 20150030595
    Abstract: The present invention relates to a myostatin inhibitor comprising extracellular water-soluble domains of delta-like 1 homolog (DLK1) as active ingredients. More particularly, the present invention relates to a composition for inhibiting myostatin activity, comprising, as active ingredients, extracellular water-soluble domains of DLK1 or a deletion mutant of extracellular water-soluble domains of DLK1. The myostatin inhibitor of the present invention is bonded to the myostatin or activin receptor type IIB so as to inhibit the action mechanism of the myostatin, to thereby promote myogenesis and prevent differentiation into fat cells. Therefore, the myostatin inhibitor of the present invention may be used in preventing and treating diseases such as muscular dysplasia that requires differentiation to muscular cells, or metabolic diseases.
    Type: Application
    Filed: January 3, 2013
    Publication date: January 29, 2015
    Inventors: Dong Hee Lee, Bum Chan Park, Jae Eun Park, Myeong Hee Jang, Seok Ho Yoo, Hye Nan Kim
  • Patent number: 8921322
    Abstract: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: December 30, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Christine Favre, Michel Auguet, Pierre-Etienne Chabrier De Lassauniere
  • Publication number: 20140370024
    Abstract: The present disclosure relates to a method of treating pain, in particular neuropathic pain, comprising administering a therapeutically effective amount of an inhibitor of VGF activity resulting from binding of VGF or a peptide of the type TLQP-21 to the receptor qC1qR. The disclosure also relates to and methods of screening for said inhibitors.
    Type: Application
    Filed: January 25, 2013
    Publication date: December 18, 2014
    Applicant: Imperial Innovations, Ltd.
    Inventors: Kenji Okuse, Alessandro Pristera
  • Publication number: 20140348750
    Abstract: Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.
    Type: Application
    Filed: December 10, 2012
    Publication date: November 27, 2014
    Inventors: Robert Vince, Swati Sudhakar More
  • Publication number: 20140336128
    Abstract: The present disclosure relates generally to fusion proteins including gigaxonin coupled to a cell penetrant peptide. These fusion proteins can be used to treat GAN in a subject in need thereof. Administration of the fusion proteins allows for control of at least one of Galectin-1 (GAL-1) levels and phosphorylated vimentin protein levels, thereby mediating aggregation of vimentin and the formation of vimentin-free zones in cells.
    Type: Application
    Filed: October 25, 2012
    Publication date: November 13, 2014
    Applicant: Indiana University Research and Technology Corporation
    Inventors: R. Mark Payne, Clifford M. Babbey, Kyle B. Martin, Samuel M. Beard
  • Patent number: 8883730
    Abstract: The present invention provides the use of formulation with surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state and increased apoptosis. Accordingly the utility of the invention can be extended in human subjects in resolution of eosinophilic inflammations in related diseases and disorders like neuromuscular and respiratory diseases with eosinophilia other than airway-hyperresponsiveness, allergy and asthma, hypereosinophilic leukemias, hypereosinophilc syndromes (rare hematological diseases), skin diseases like eosinophilia-Myalgia syndrome, eosinophilic fascitis, capillary leak syndromes (IL-2), Churg-Strauss syndrome, toxic oil syndrome, parasitosis, etc., where a large number of stimulated eosinophils accumulate and release a series of growth factors, cytokines, chemokines, bioactive lipid mediators, toxic oxygen metabolites.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: November 11, 2014
    Assignee: Council of Scientific and Industrial Research
    Inventors: Lakshna Mahajan, Taruna Madan, Puranam Usha Sarma, Uday Kishore
  • Publication number: 20140315823
    Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.
    Type: Application
    Filed: May 15, 2014
    Publication date: October 23, 2014
    Applicant: Duke University
    Inventors: Daniel T. Laskowitz, Hana Dawson, Brad Kolls
  • Publication number: 20140301982
    Abstract: Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (C6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal. Additional applications include use in the treatment of multiple sclerosis either alone or in combination with another drug.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 9, 2014
    Applicant: REGENESANCE B.V.
    Inventors: Frank BAAS, Kees FLUITER
  • Patent number: 8846615
    Abstract: The present invention relates to novel Motoneuronotrophic Factors (MNTF) peptides and analogs thereof, including compositions capable of promoting the growth and viability of neurons. MNTF peptides between two and six amino acids in length are provided, as well as analogs of these MNTF peptides that are modified by covalent attachment to another moiety. Other embodiments are described herein.
    Type: Grant
    Filed: February 23, 2009
    Date of Patent: September 30, 2014
    Assignee: Genervon Biopharmaceuticals, LLC
    Inventors: Pui-Yuk Dorothy Ko, Mark S. Kindy
  • Patent number: 8828389
    Abstract: The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent. The invention also relates to novel amyotrophic lateral sclerosis-specific epitopes and their uses to make antibodies, and to the novel antibodies and uses thereof.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: September 9, 2014
    Assignee: Amorfix Life Sciences Ltd.
    Inventor: Neil Cashman
  • Publication number: 20140249088
    Abstract: The disclosure relates, at least in part, to methods of treating neuropathic pain in a patient in need thereof by administering an effective amount of a disclosed compound, e.g. a peptide NMDA receptor partial agonist.
    Type: Application
    Filed: September 27, 2013
    Publication date: September 4, 2014
    Inventor: Joseph Moskal
  • Patent number: 8796216
    Abstract: The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumor cell, preferably via a somatostatin or cortistatin receptor, a GHRH receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a KiSS-1 receptor or a prolactin-releasing peptide receptor. When so delivered, the protease is internalized and inhibits secretion from said tumor cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: August 5, 2014
    Assignee: Syntaxin Limited
    Inventors: Stephen Johnstone, Philip Marks, Keith Foster
  • Patent number: 8791076
    Abstract: The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: July 29, 2014
    Inventors: Pablo Villoslada, Angel Messeguer
  • Patent number: 8778885
    Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: July 15, 2014
    Assignee: Amorfix Life Sciences Ltd.
    Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
  • Patent number: 8754036
    Abstract: An object of the present invention is to provide a substance which is able to be an active ingredient for the improvement of dysfunction caused by nerve damage. An improving agent for dysfunction due to nerve damage of the present invention as a means for resolution thereof is characterized in that it comprises an endo-?-N-acetylglucosaminidase type enzyme which hydrolyzes an N-acetylglucosamide bond in a keratan sulfate backbone as an active ingredient. When the improving agent of the present invention is administered, clinical improvement is achieved in motor neuron dysfunction and sensory neuron dysfunction such as neuropathic pain represented by a pain caused by allodynia and hyperalgesic reaction of the object to be treated.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: June 17, 2014
    Assignees: National University Corporation Nagoya University, Seikagaku Corporation
    Inventors: Kenji Kadomatsu, Yukihiro Matsuyama, Akiomi Tanaka, Sawako Takeshita
  • Patent number: 8748384
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: June 10, 2014
    Assignee: H. Lundbeck A/S
    Inventors: Olav Michael Andersen, Anders Nykjaer
  • Publication number: 20140135262
    Abstract: The present invention relates generally to the field of neuronal health and neuronal protection. One embodiment of the present invention relates to a composition that can be used for the protection of the enteric nervous system from neurodegeneration. Disorders linked to an impaired enteric nervous system can be treated or prevented by the administration of lactoferrin containing compositions according to the present invention.
    Type: Application
    Filed: November 6, 2013
    Publication date: May 15, 2014
    Applicant: NESTEC S.A.
    Inventors: Magali Faure, Bing Wang, Jeroen Schmitt
  • Patent number: 8716231
    Abstract: The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as described herein. The present invention is further directed to methods for the treatment of pain comprising co-therapy with analgesic agent(s) and a compound of formula (I) or formula (II) as described herein.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: May 6, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Virginia L. Smith-Swintosky, Allen B. Reitz
  • Patent number: 8716223
    Abstract: A synthetic peptide sequence demonstrating neuroprotective and anti-inflammatory functions is disclosed. Methods of use for the synthetic peptide are also provided.
    Type: Grant
    Filed: May 5, 2009
    Date of Patent: May 6, 2014
    Assignee: Drexel University
    Inventors: Timothy J. Cunningham, Lihua Yao
  • Patent number: 8716220
    Abstract: The present disclosure provides compositions containing a leptin product and methods of clinical therapy and diagnostic methods for progressive cognitive disorders. According to one aspect, the described invention provides a method for treating a progressive cognitive disorder. According to another aspect, the described invention provides a method for improving resilience of cognitive function in a subject in need thereof. According to another aspect, the described invention provides a method for identifying an effective therapeutic agent for treating a progressive cognitive dysfunction disease or disorder that results from at least one of accumulation of A?, hyperphosphorylation of tau, or accumulation of neurofibrillary tangles.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: May 6, 2014
    Inventors: Nikolaos Tezapsidis, Steven J. Greco, Mark Smith
  • Patent number: 8709422
    Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2).
    Type: Grant
    Filed: December 24, 2010
    Date of Patent: April 29, 2014
    Assignee: Amorfix Life Sciences Ltd.
    Inventors: Neil R. Cashman, Joachim Bernhard Ostermann, Avijit Chakrabartty, Rishi Rakhit
  • Patent number: 8703136
    Abstract: The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: April 22, 2014
    Assignee: Regenesance B.V.
    Inventors: Frank Baas, Valeria Ramaglia
  • Patent number: 8703711
    Abstract: Methods, uses, agents and compositions useful for the prevention, treatment and/or diagnosis of neuroinflammatory conditions such as multiple sclerosis and spinal cord injury based on the modulation of nerve injury-induced protein-1 (Ninjurin-1) are disclosed.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: April 22, 2014
    Assignee: Val-Chum, Limited Partnership
    Inventors: Alexandre Prat, Simone Terouz, Igal Ifergan, Hania Kebir
  • Patent number: 8691765
    Abstract: A method of stimulating neuronal growth or repair comprising exposing a target neuron or neuronal area to a solution of the metallothionein isoform MT-IIA.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: April 8, 2014
    Assignee: University of Tasmania
    Inventors: Adrian Keith West, Meng Inn Chuah, James Clement Vickers, Roger Steven Chung
  • Patent number: 8691766
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: April 8, 2014
    Assignee: Brown University Research Foundation
    Inventors: Justin R. Fallon, Beth A. McKechnie, Michael Rafii, Hilliary Creely, Mark A. Bowe, Alison R. Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Publication number: 20140086981
    Abstract: Peptides of general formula (I): R1—Wn—Xm-AA1-AA2-AA3-AA4-AA5-AA6-Yp—Zq—R2 their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, a preparation process, cosmetic or pharmaceutical compositions which contain them and their use in the treatment and/or care of conditions, disorders and/or diseases which improve or are prevented by PGC-1? modulation.
    Type: Application
    Filed: March 23, 2012
    Publication date: March 27, 2014
    Inventors: José María García Antón, Nuria Almiñana Domenech, Antonio Vicente Ferrer Montiel
  • Publication number: 20140080753
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 20, 2014
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Kevin D. SHENK, Francesco PARLATI, Han-jie ZHOU, Catherine SYLVAIN, Mark S. SMYTH, Mark K. BENNETT, Guy J. LAIDIG
  • Publication number: 20140057845
    Abstract: In order to provide a composition for treating, improving, or preventing pain, it has been found out that a metallothionein protein is expressed in a normal peripheral nerve, and that the expression is not observed in a peripheral nerve producing pain. Moreover, it has been found out that administering metallothionein to rats having neuropathic pain suppresses the pain in the rats.
    Type: Application
    Filed: February 23, 2012
    Publication date: February 27, 2014
    Applicant: SAPPORO MEDICAL UNIVERSITY
    Inventors: Yasuo Kokai, Gousuke Ooki, Kayo Matsumoto, Shinichi Imai, Takuro Wada
  • Patent number: 8658596
    Abstract: The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
    Type: Grant
    Filed: September 14, 2010
    Date of Patent: February 25, 2014
    Assignee: Brown University Research Foundation
    Inventors: Justin R. Fallon, Mark A. Bowe, Beth McKechnie, Michael Rafii, Alison Amenta, Mary Lynn Mercado, Hiroki Hagiwara
  • Publication number: 20140045764
    Abstract: A method of treating a neurodegenerative disorder is disclosed. The method comprises administering to the subject a therapeutically effective amount of an isolated peptide comprising at least 3 amino acids of a CD44V10 amino acid sequence no more than 20 amino acids of said CD44V10 amino acid sequence and comprising a neuroprotective activity.
    Type: Application
    Filed: March 22, 2012
    Publication date: February 13, 2014
    Applicant: Neurim Pharmaceuticals (1991) Ltd.
    Inventors: Elhanan Pinner, Nava Zisapel
  • Publication number: 20140038898
    Abstract: Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.
    Type: Application
    Filed: March 16, 2012
    Publication date: February 6, 2014
    Applicant: Duke University
    Inventors: Daniel T. Laskowitz, Hana Dawson, Brad Kolls
  • Patent number: 8642732
    Abstract: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: February 4, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Anthony Rossomando
  • Patent number: 8642543
    Abstract: The described invention provides methods for treating or preventing progression of a progressive cognitive disease, disorder or condition, and methods for improving resilience of cognitive function in a subject in need thereof.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: February 4, 2014
    Assignee: Neurotez, Inc.
    Inventors: Nikolaos Tezapsidis, Steven Greco, Mark Smith
  • Patent number: 8642552
    Abstract: The invention relates to human medicine and to the use of epidermal growth factor (EGF) for preparing a pharmaceutical composition which is administered by infiltration into the periphery of nerve ganglia and/or trunks for the morphofunctional restoration of peripheral nerves in painful sensory-motor neuropathy as well as manifestations of ischemic neuritis. The invention also includes a composition containing EGF which can be formulated together with anesthetics or analgesics or encapsulated in microspheres and to the use thereof for the morphofunctional restoration of peripheral nerves in painful sensitive-motor-type diabetic neuropathy and the manifestations of ischemic neuritis.
    Type: Grant
    Filed: October 1, 2007
    Date of Patent: February 4, 2014
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Jose Ignacio Fernandez Montequin, Luis Saturnino Herrera Martinez, Jorge Amador Berlanga Acosta, Diana Garcia Del Barco Herrera, Danay Cibrian Vera, Gerardo Enrique Guillen Nieto, Raimundo Ubieta Gomez, Sonia Gonzalez Blanco, Vivian Maria Saez Martinez
  • Patent number: 8637567
    Abstract: This invention provides compounds, compositions and methods for treating a cognitive disorder or memory disorder in animals that result from aging or other neurodegenerative condition. In particular, compounds of this invention can stimulate neural cell growth, increased amounts of cells containing a key enzyme needed for production of the cholinergic neurotransmitter, and can improve memory and cognitive function in animals who have experienced a loss of memory or cognitive function.
    Type: Grant
    Filed: October 13, 2010
    Date of Patent: January 28, 2014
    Assignee: Neuren Pharmaceuticals Ltd.
    Inventors: Peter David Gluckman, Jian Guan, Mary-Anne Woodnorth, Margaret Anne Brimble
  • Publication number: 20130338075
    Abstract: The present invention generally relates to methods and compositions for preventing or treating axonal and/or neuronal degeneration in a subject by administering a composition comprising a peptide that comprises the amino acid sequence Arginine-Glycine-Aspartate (RGD).
    Type: Application
    Filed: June 13, 2013
    Publication date: December 19, 2013
    Inventor: Thien Nguyen
  • Patent number: 8592374
    Abstract: The present invention relates to a neurotrophic peptide having an amino acid sequence of VGDGGLFEKKL (SEQ ID NO:1), EDQQVHFTPTEG (SEQ ID NO:2) or IPENEADGMPATV (SEQ ID NO:3), and comprising an adamantyl group at the C- and/or N-terminal end.
    Type: Grant
    Filed: March 9, 2011
    Date of Patent: November 26, 2013
    Assignee: Research Foundation for Mental Hygiene, Inc.
    Inventors: Herbert Mösler, Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 8592378
    Abstract: The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: November 26, 2013
    Assignee: Telsar Pharma Inc.
    Inventors: Takanao Otsuka, Hirotsugu Ueda, Keiko Fujie, Hideyuki Muramatsu, Michizane Hashimoto, Shigehiro Takase
  • Publication number: 20130287755
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: April 28, 2011
    Publication date: October 31, 2013
    Applicants: PANGU BIOPHARMA LIMITED, ATYR PHARMA, INC.
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain Philippe Vasserot, Wing-Sze Lo, Jeffry Dean Watkins, Cheryl L. Quinn, John D. Mendlein